• BridgeBio Pharma Inc BBIO.OQ reported a quarterly adjusted loss of $1.10​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $-1.08. The mean expectation of sixteen analysts for the quarter was for a loss of 98 cents per share. Wall Street expected results to range from $-1.13 to -33 cents per share.

• Revenue fell 33.2% to $2.73 million from a year ago; analysts expected $3.76 million.

• BridgeBio Pharma Inc's reported EPS for the quarter was a loss of 86 cents​.

• The company reported a quarterly loss of $162.04 million.

• BridgeBio Pharma Inc shares had risen by 2.6% this quarter and lost 35.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for BridgeBio Pharma Inc is 46.00

This summary was machine generated from LSEG data November 12 at 03:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)